Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial
- DOI
- 10.1186/s13223-020-0409-3
- Published
- 2020-02-04
- Container
- Allergy, Asthma & Clinical Immunology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s13223-020-0409-3,
title = {Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial},
author = {Donald S. Levy and Henriette Farkas and Marc A. Riedl and Florence Ida Hsu and Joel P. Brooks and Marco Cicardi and Henrike Feuersenger and Ingo Pragst and Avner Reshef},
year = {2020},
journal = {Allergy, Asthma \& Clinical Immunology},
doi = {10.1186/s13223-020-0409-3},
url = {https://doi.org/10.1186/s13223-020-0409-3}
}RIS
TY - JOUR TI - Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial AU - Donald S. Levy AU - Henriette Farkas AU - Marc A. Riedl AU - Florence Ida Hsu AU - Joel P. Brooks AU - Marco Cicardi AU - Henrike Feuersenger AU - Ingo Pragst AU - Avner Reshef PY - 2020 JO - Allergy, Asthma & Clinical Immunology DO - 10.1186/s13223-020-0409-3 UR - https://doi.org/10.1186/s13223-020-0409-3 ER -
APA
Levy, D. S., Farkas, H., Riedl, M. A., Hsu, F. I., Brooks, J. P., Cicardi, M., Feuersenger, H., Pragst, I., & Reshef, A. (2020). Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial. Allergy, Asthma & Clinical Immunology. https://doi.org/10.1186/s13223-020-0409-3
Source records
- crossref · retrieved 2026-09-27T09:23:29.604Z